-=Onconova Therapeutics (ONTX) : IV rigosertib did not meet primary endpoint

IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS)

Onconova will focus on promising pipeline opportunities including with its CDK4/6 + ARK5 inhibitor ON 123300

NEWTOWN, Pa., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that INSPIRE, the company’s pivotal Phase 3 study assessing the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients, did not meet its primary endpoint of improved survival.